KẾT QUẢ ĐIỀU TRỊ UNG THƯ CỔ TỬ CUNG TÁI PHÁT, DI CĂN XA BẰNG PHÁC ĐỒ CISPLATIN – PACLITAXEL TẠI BỆNH VIỆN K GIAI ĐOẠN 2017-2022

Abstract

Objective: This study aims to describe some clinical and subclinical characteristics of patients with recurrent or distant metastatic cervical cancer and to evaluate the treatment outcomes of the cisplatin-paclitaxel regimen administered at K Hospital during the period 2017–2022. Patients and methods: 51 patients diagnosed with recurrent or distant metastatic cervical cancer received treatment with the cisplatin-paclitaxel regimen at K Hospital from 2017 to 2022, evaluating the response, and some toxicities. Result: The mean age was 52.5 ± 8.3 years old. The predominant histopathological subtype was squamous cell carcinoma, accounting for 82.4%. Among the cohort, 53.7% of patients had undergone surgery combined with radiation therapy before experiencing relapse. The mean time to relapse after the initial treatment was 14.9 ± 9.9 months. The majority of patients (68.7%) experienced relapse at two or more sites. The overall response rate to the cisplatin-paclitaxel regimen was 51%. Our analysis revealed that the treatment received before relapse was significantly associated with treatment response. The toxicities of the regimen were low, with the majority of patients experiencing grade 1 or 2 toxicities. Patients with grade 3/4 neutropenia accounted for 13.8%. Conclusion: Chemotherapy with the cisplatin - paclitaxel regimen has high efficacy and acceptable toxicity in the treatment of patients with recurrent or metastatic cervical cancer.